Brain mets under I.O.

Size: px
Start display at page:

Download "Brain mets under I.O."

Transcription

1 Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France

2 Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS, Novartis, Pfizer Research Grants from BMS, Novartis, Pfizer

3 What do we know about Brain Mets in RCC? They represent 8% of all metastases in RCC They increase over time, and probably with longer survival They are poor prognostic factor

4 What do we know about Brain Mets in RCC? They represent 8% of all metastases in RCC They increase over time, and probably with longer survival They are poor prognostic factor TKIs have (very) little efficacy (Chevreau et al, Ann Oncol ) They have high impact on QoL They are exclusion criteria from most of pivotal trials

5 What do we know about lymphocyte infiltration in BMs? (Berghof et al, ASCO 2016 educational) Highly heterogenous PDL1 expression tends to be higher in BM from NSCLCC than in paired primary Patients with dense infiltration of effector cells in BM have better prognosis Density of infiltration differs between tumor (melanoma>breast) Interaction between the blood-tumor and the blood-brain barrier swith the infiltration zone of a BM unknown

6 What do we know about PD1/PDL1 expression in BM? Personal experience will be presented at ASCO 2017 Comparison between BM, pancreatic mets and primary tumors: 180 resected RCC specimen collected 42 primary tumors 138 metastases 87 BM 51 Pancreatic metastases (PM) Derosa L et al, ASCO 2017

7 Inter and intra-tumor heterogeneity of PD-L1 and MET expression in mrcc Biomarker expression Primary RCC Metastases All specimens PM BM p value All All sample (n=180) PD-L1 TC 12% 19% 23% % 22% PD-L1 IC 51% 49% 47% % 51% MET 0% 2% 35% < % 23% Lower expression of PD-L1 and MET in primary RCC compared to metastases and a significant higher expression of MET in BM compared to PM PD-L1 discordance was higher in metachronous metastases (>6months). Biomarker expression Discordance between primary tumor and metasteses PM BM Paired samples (n=35) PD-L1 TC 15% 40% PD-L1 IC 33% 22% MET 0% 67% PD-L1 positivity was correlated to higher Fuhrman grade (p<0.02), PDL-L1 IC to TIL (p<0.02) and MET to TIL (p=0.013) and to necrosis (p<0.0001). Derosa et al, poster ASCO 2017.

8 Efficacy of IO in BM from different tumors Melanoma: Ipilimumab PD1 antibodies Lung Cancer Renal Cancer

9 Experience in Melanoma (courtesy of K Margolin and H Kugler) Ipilimumab EAPexperience 51 patients with BM without steroids nor surgery 21 patients with BM and steroids

10 Proportion Alive Ipilimumab in advanced melanoma: pooled OS, including EAP data; N = Median OS, months (95% CI): 9.5 ( ) year OS rate, % (95% CI): 21 (20 22) Ipilimumab CENSORED Months Patients at Risk Ipilimumab Schadendorf et al. JCO 2015

11 Brain mets: Ipi 10 mg/kg x 4 + maintenance Cohort A=no steroid or neuro Sx ~26% 2 yr OS also seen in 165-pt cohort from expanded access trial PLATEAU Margolin et al Lancet Oncology 2012

12 Disease control at 12 weeks

13 Nivolumab + Ipilimumab in melanoma BM ASCO 2017

14 Phase II Trial of Pembrolizumab for Untreated BM Key Eligibility: Advanced NSCLC or melanoma At least 1 untreated brain metastasis 5-20mm No neurologic symptoms or steroid requirement Pembrolizumab 10mg/kg q2 weeks Brain metastasis PD Brain metastasis CR, PR, or SD Consider radiation or surgery to progressing lesions Continue pembrolizumab if systemic control achieved PI: Harriet Kluger Co-PIs: Veronica Chiang, Sarah Goldberg Primary Endpoint: Brain Metastasis Response Rate Secondary Endpoints: Overall response rate, safety, PFS, OS Exploratory Endpoints: PD-L1 expression, TILs, and other predictive biomarkers on T cells, tumor cells, neuronal cells, and in plasma

15 Pembrolizumab in BM from melanoma and NSCLCC Goldberg et al, Lancet Oncol 2016

16 Examples of responders 56 year old male, progressed on 2 prior regimens; response to pembro at 2 months, remains in response, 33+ months 53 year old male, prior progression after adoptive cell therapy at NCI, response to pembro at 2 months, remains in response, 6+ months, still in response

17 Patient with pseudoprogression Baseline A B Pre-treatment: A) H+E B) S100 C D After 1 dose, biopsy of target-like growing lesion: C) H+E D) HMB45 After 1 dose, confusion E F E) Reactive astrocytosis, macrophages F) CD45 G H G) CD8 H) CD68

18 Experience in Lung Cancer N=36 (18 melanoma, 18 PD-L1+* NSCLC patients) 1 untreated or progressive brain metastasis (5 and 20 mm in diameter) without associated neurological symptoms or the need for corticosteroids. Pembrolizumab 10 mg/kg every 2 weeks until PD. Brain response in NSCLC patients: 33% Median DoR: months *>1% tumoral cell + 18 Goldberg -Lancet Oncol 2016

19 Experience from IGR in NSCLCC (courtesy of B Besse) 38 of 238 patients (16%) treated in GR with PD1/PDL1 inhibitors had BMs 31 pts with BM 4 pts with BM and meningeal carcinomatosis 3 pts with meningeal carcinomatosis 13% progression in the brain 28% (2/7) patients with meningeal carcinomatosis progressed

20 Experience from IGR in NSCLCC (courtesy of B Besse) Safety is acceptable Overall response in patients with BM: 18 PD= 55% 6 PR= 18% 9 SD= 27%

21 What do we know in RCC? Preliminary experience from IGR reported at GU ASCO mrcc patients treated with Nivolumab within the Nivoren trial 8 patients with asymptomatic brain metastases (BM) at baseline Albiges L et al. Abstract 520

22 intracranial PD and lung PR No systemic extracranial PD Intracranial PD No apparent benefit of Nivo on BM Brain imaging before starting Nivo

23 Larger experience will be reported at ASCO 2017 up to December 2016, 588 pts have been enrolled including 55 pts with BM (35 (67%),6 (12%) and 11 (21%) with 1, 2 or > 2 BM No previous treatment for BM was performed in 67% (n = 37), while 9% had previous brain surgery (n = 5 ;) or brain radiation (n = 17 (31%). Neurologic deterioration requiring steroids was observed in 15 pts (32%)

24 Efficacy data: dissociated response in the brain is not uncommon Baseline 4 weeks FON.

25 Efficacy data: dissociated response in the brain is not uncommon Baseline 8 weeks HAL.

26 Efficacy data: dissociated response in the brain is not uncommon Baseline 8 weeks HOD.

27 LOU.. Baseline 8 weeks

28 Baseline 8 weeks 16 weeks MAY

29 Questions Are these brain progression pseudoprogression or real preprogression? One of our patient had surgery, and had viable tumor cells When a second scan was performed, progression continued Stereotactic radiotherapy was used in most patients with good efficacy

30 Preliminary conclusions from Nivoren Safety of Nivolumab in RCC patients with BM appears to be acceptable, although some pts do require steroids because of brain progressive disease. Previously untreated BM commonly progress on nivolumab, and requires therapy Overall 23% of patients had objective response, mainly after previous local treatment

31 CONCLUSIONS Brain mets can be treated with IO Efficacy data might be different according to tumor type Very few data are available in RCC: Preliminary data from Nivoren suggest that it is feasible That it is safe in previously treated patients But that rapid progression in the brain can occur With some dissociated response More data are required to asses the final efficacy

Overview: Immunotherapy in CNS Metastases

Overview: Immunotherapy in CNS Metastases Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris

More information

Developping the next generation of studies in RCC

Developping the next generation of studies in RCC Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,

More information

Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases

Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital

More information

Special Situation: Brain metastases

Special Situation: Brain metastases ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department

More information

Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care

Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland

More information

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,

More information

Immunotherapy for the Treatment of Brain Metastases

Immunotherapy for the Treatment of Brain Metastases Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy

More information

Toxicity from Checkpoint Inhibitors. James Larkin FRCP PhD

Toxicity from Checkpoint Inhibitors. James Larkin FRCP PhD Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech

More information

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March

More information

Immunotherapy & radiotherapy

Immunotherapy & radiotherapy Immunotherapy & radiotherapy Eric Deutsch MD PhD Gustave Roussy Cancer Campus Image courtesy of Gustave Roussy Institute Disclosure & Disclaimer An honorarium is provided by Accuray for this presentation

More information

ESMO Translational Research Fellowship (November 2015 November 2017) Lisa Derosa FINAL REPORT

ESMO Translational Research Fellowship (November 2015 November 2017) Lisa Derosa FINAL REPORT ESMO Translational Research Fellowship (November 2015 November 2017) Lisa Derosa FINAL REPORT Host Institute: Institute Gustave Roussy, Villejuif, France Mentor: Dr. Bernard Escudier Project title: The

More information

III Sessione I risultati clinici

III Sessione I risultati clinici 10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it

More information

Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?

Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?

More information

The Immunotherapy of Oncology

The Immunotherapy of Oncology The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant

More information

Fifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA

Fifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee

More information

La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD

La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications

More information

Management of Brain Metastases Sanjiv S. Agarwala, MD

Management of Brain Metastases Sanjiv S. Agarwala, MD Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):

More information

Nivolumab: esperienze italiane nel carcinoma polmonare avanzato

Nivolumab: esperienze italiane nel carcinoma polmonare avanzato NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale

More information

Treating Multiple. Brain Metastases (BM)

Treating Multiple. Brain Metastases (BM) ESTRO 36 5-9 May 2017, Vienna Austria, Accuray Symposium Treating Multiple Brain Metastases (BM) with CyberKnife System Frederic Dhermain MD PhD, Radiation Oncologist Gustave Roussy University Hospital,

More information

Immunotherapy, an exciting era!!

Immunotherapy, an exciting era!! Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy

More information

Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China

Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not

More information

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in

More information

Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker

Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction

More information

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26

More information

Treatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC

Treatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

Renal Cell Carcinoma: Systemic Therapy Progress and Promise

Renal Cell Carcinoma: Systemic Therapy Progress and Promise Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.

More information

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University

Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,

More information

Renal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy

Renal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures

More information

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy

More information

Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group

Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial

More information

The Really Important Questions Current Immunotherapy Trials are Not Answering

The Really Important Questions Current Immunotherapy Trials are Not Answering The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway

More information

Take home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone

Take home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017

More information

Radiation Therapy and Immunotherapy: New Frontiers

Radiation Therapy and Immunotherapy: New Frontiers Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical

More information

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE

More information

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy

More information

Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?

Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias

More information

Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016

Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity

More information

Immunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center

Immunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated

More information

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single

More information

Weitere Kombinationspartner der Immunotherapie

Weitere Kombinationspartner der Immunotherapie 1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for

More information

Immunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France

Immunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data

More information

Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy

Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures

More information

IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS

IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role

More information

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual

More information

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy

More information

Melanoma: Immune checkpoints

Melanoma: Immune checkpoints ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto

More information

Immunotherapy for Renal Cell Carcinoma. James Larkin

Immunotherapy for Renal Cell Carcinoma. James Larkin Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech

More information

Cytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center

Cytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,

More information

WHAT S HOT IN MELANOMA CNS METASTASES?

WHAT S HOT IN MELANOMA CNS METASTASES? WHAT S HOT IN MELANOMA CNS METASTASES? GIUSEPPE MINNITI, MD, PHD Radiation Unit, UPMC, Hillman Cancer Center, San Pietro Hospital, Rome, and IRCCS Neuromed, Pozzilli (IS), Italy Marseille, September 21-22,

More information

Immunoterapia di 1 linea Evidenze e Prospettive Future

Immunoterapia di 1 linea Evidenze e Prospettive Future Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures

More information

CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer

CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,

More information

News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital

News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and

More information

New Systemic Therapies in Advanced Melanoma

New Systemic Therapies in Advanced Melanoma New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity

More information

Immunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)

Immunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS) Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers

More information

Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey

Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey Updated Oncology 2015: State of the Art News & Challenging Topics CURRENT STATUS OF STEREOTACTIC RADIOSURGERY IN BRAIN METASTASES Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey Bucharest,

More information

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal

More information

Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento

Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara

More information

Optimal Management of Isolated HER2+ve Brain Metastases

Optimal Management of Isolated HER2+ve Brain Metastases Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not

More information

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy

More information

MELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona

MELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J

More information

Immunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017

Immunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017 Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in

More information

Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial

Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,

More information

Immune checkpoint blockade in lung cancer

Immune checkpoint blockade in lung cancer Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data

More information

Practice changing studies in lung cancer 2017

Practice changing studies in lung cancer 2017 1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received

More information

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix

More information

We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications

We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives

More information

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1 Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND

More information

Efficacy of anti-pd-1 therapy in patients with melanoma brain metastases

Efficacy of anti-pd-1 therapy in patients with melanoma brain metastases Efficacy of anti-pd-1 therapy in patients with melanoma brain metastases John J. Park 1, Sagun Parakh 2,3,4, Shehara Mendis 5, Rajat Rai 6, Wen Xu 7, Serigne Lo 6, Martin Drummond 6, Catherine Rowe 7,

More information

Current experience in immunotherapy for metastatic renal cell carcinoma

Current experience in immunotherapy for metastatic renal cell carcinoma Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,

More information

Brain metastases: future developments. Emilie Le Rhun Lille, France

Brain metastases: future developments. Emilie Le Rhun Lille, France Brain metastases: future developments Emilie Le Rhun Lille, France Disclosures ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from

More information

Ipilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008

Ipilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008 Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute

More information

How do weimplementimmunotherapyin routine practice? Lessons from the lung cancer experience

How do weimplementimmunotherapyin routine practice? Lessons from the lung cancer experience How do weimplementimmunotherapyin routine practice? Lessons from the lung cancer experience Pr Alexis Cortot, M.D., Ph.D. Thoracic Oncology Department, CHRU Lille Institut of Biology, Lille TAO Paris,

More information

Immunotherapy for the Treatment of Cancer

Immunotherapy for the Treatment of Cancer Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,

More information

Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara

Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara CNS metastases in HER2+ BC The proportion of patients with HER2+ advanced breast cancer who have CNS metastases

More information

Sequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC

Sequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi

More information

Largos Supervivientes, Tenemos datos?

Largos Supervivientes, Tenemos datos? Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot

More information

Basic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA

Basic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer

More information

Combined treatment of Brain metastases: Radiosurgery and Targeted therapy

Combined treatment of Brain metastases: Radiosurgery and Targeted therapy Combined treatment of Brain metastases: Radiosurgery and Targeted therapy Stephanie Kroeze, MD PhD OVERVIEW Introduction brain metastases Targeted therapy as monotherapy Efficacy of SRS combined with Targeted

More information

WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example

WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca

More information

Emerging Biomarkers of VEGF and mtor Inhibitors in 2015

Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non small cell lung

More information

CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT

CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

Brain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland

Brain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients

More information

Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel

Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,

More information

Developmental Therapeutics for Genitourinary Malignancies

Developmental Therapeutics for Genitourinary Malignancies Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following

More information

Checkpointinhibitoren in der Uro-Onkologie. Carsten Grüllich

Checkpointinhibitoren in der Uro-Onkologie. Carsten Grüllich Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer

More information

Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea

Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12

More information

Prostate cancer Management of metastatic castration sensitive cancer

Prostate cancer Management of metastatic castration sensitive cancer 18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial

More information

ONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing

ONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma

More information

ASCO 2018 Investor Meeting

ASCO 2018 Investor Meeting ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for

More information

Revisione Oral Abstracts

Revisione Oral Abstracts Revisione Oral Abstracts Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi UPDATES and NEWS from the Genitourinary Cancers Symposium - Milano,

More information

Will All Adjuvant Therapy Trials Be Negative in RCC?

Will All Adjuvant Therapy Trials Be Negative in RCC? Will All Adjuvant Therapy Trials Be Negative in RCC? Tim Eisen Eleventh European International Kidney Cancer Symposium 29-30 April 2016 Crowne Plaza Barcelona Fira Center, Barcelona, Spain Tim Eisen -

More information

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program

More information

Historical overview of immunotherapy

Historical overview of immunotherapy Historical overview of immunotherapy Before introduction of immune checkpoint inhibitors John B.A.G. Haanen, MD PhD My Disclosures I have provided consultation, attended advisory boards, and/or provided

More information

Managing immune related toxicity. Karijn Suijkerbuijk May 27 th 2017

Managing immune related toxicity. Karijn Suijkerbuijk May 27 th 2017 Managing immune related toxicity Karijn Suijkerbuijk May 27 th 2017 Disclosures Advisory role: BMS, Merck Travel support: Amgen, Novartis, Roche Whybother? Patients are dying from toxicity Eggermont ipilimumab

More information

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells

More information